Chester County News and Community Website
RADNOR, PA — Mineralys Therapeutics (Nasdaq: MLYS) will present new clinical data on its investigational hypertension treatment lorundrostat at ENDO 2026, as the company advances the drug through late-stage development …
Mineralys Data Presentation Highlights Heart Failure Biomarkers Ahead of FDA Review Read More
WILMINGTON, DE — Mirum Pharmaceuticals (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) are set to present pivotal Phase 2 clinical data for investigational fibrodysplasia ossificans progressiva (FOP) treatment zilurgisertib this week, …
Mirum, Incyte Advance FOP Drug as FDA Review Continues Read More
WILMINGTON, DE — AstraZeneca (LSE/STO/NYSE: AZN) reported Phase III trial results showing that a combination of its immunotherapy drugs IMFINZI and IMJUDO with lenvatinib and transarterial chemoembolization (TACE) significantly delayed …
AstraZeneca Liver Cancer Regimen Extends Progression-Free Survival in Phase III Trial Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has submitted a registrational study protocol to the U.S. Food and Drug Administration for its SkinJect therapy in Gorlin syndrome, a rare …
ICYMI: Medicus Advances SkinJect Into Registrational Study for Rare Disorder Read More
PHILADELPHIA, PA — Cabaletta Bio (Nasdaq: CABA) reported new clinical data suggesting its lead CAR-T cell therapy candidate could support regulatory filings in multiple autoimmune diseases, prompting the company to …
Cabaletta Expands Autoimmune Strategy on Mid-Stage Data Read More
KING OF PRUSSIA, PA — SEED Therapeutics has advanced its lead cancer drug candidate, ST-01156, into a first-in-human clinical trial, a step that will test whether the company’s molecular glue …
SEED Advances Cancer Drug Into Human Trials, Targets Hard-to-Treat Tumors Read More
DOYLESTOWN, PA — Aprea Therapeutics reported early signs of anti-tumor activity from its ongoing Phase 1 trial of experimental cancer therapy APR-1051, with partial responses observed in patients with advanced …
Aprea Reports Early Tumor Responses in Phase 1 APR-1051 Study Read More WILMINGTON, DE — Incyte reported Phase 3 trial results showing that adding tafasitamab and lenalidomide to the standard R-CHOP regimen reduced the risk of disease progression or death in patients …
Incyte Study Shows Lymphoma Regimen Extends Progression-Free Survival Read More
PHILADELPHIA, PA — Virion Therapeutics reported new long-term data showing its experimental hepatitis B immunotherapy, VRON-0200, produced sustained reductions in key disease markers for more than two years after a …
Virion Reports Long-Term Hepatitis B Response in Early Trial Read More
CONSHOHOCKEN, PA — Tiger BioSciences reported interim results from a randomized controlled clinical trial showing that patients with non-healing diabetic foot ulcers treated with its caregraFT™ placental membrane allograft alongside …
Tiger BioSciences Reports Interim Trial Data Showing Higher Diabetic Ulcer Closure Rates Read More